长风药业 02652Prospectus Information

Prospectus Information
返回 Stock Info Prospectus Allotment Results Allotment Profile Expected Lots
IPO Timeline
Broker Deadline
2025-10-02
Morning deadline
HKEX Deadline
2025-10-02
Noon deadline
Broker Results (T-2)
2025-10-03
Some brokers release in afternoon
Grey Market (T-1)
2025-10-06
Afternoon
HKEX Allotment (T-1)
2025-10-06
Evening
Registrar Allotment (T-1)
2025-10-06
Evening
Listing Day (T)
2025-10-08
First day of trading
Company Overview
Stock Name长风药业
Stock Code02652
Company Full Name长风药业
IndustryBiotech & Pharma
Principal Activitiescornerstone of successful inhalation formulations
Listing Date2025-10-08
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)Suzhou Jiangsu PRC Principal Place of Business in 31/F., Tower Two Hong Kong Times Square, 1 Matheson Street Causeway Bay Hong Kong
Business Address (Hong Kong)香港 銅鑼灣 勿地臣街1號時代廣場 二座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.cfpharmtech.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar ContactComputershare Hong Kong Investor
A-Share/US Dual ListingNo
Offering Information
Offering Mechanism Large IPO Exempt
Offer PriceHK$ 14.75 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 7,375
Par ValueRMB 1.0 / shares
Offer Period2025-09-26 to 2025-10-02
Global Offering Shares41,198,000 shares
HK Public Offer Shares (Initial)4,120,000 shares (10.0%)
Public Offer Lots (Initial)8,240lots (4,120lots, 4,120lots)
International Placing Shares (Initial)37,078,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO411,978,387 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share0%
Clawback Tiers机制B-无回补
Reallocation OptionNo
Total Global Offering SizeHK$ 607,670,500
Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 7,375
2 lots 1,000 HK$ 14,750
3 lots 1,500 HK$ 22,125
4 lots 2,000 HK$ 29,500
5 lots 2,500 HK$ 36,875
6 lots 3,000 HK$ 44,250
7 lots 3,500 HK$ 51,625
8 lots 4,000 HK$ 59,000
9 lots 4,500 HK$ 66,375
10 lots 5,000 HK$ 73,750
12 lots 6,000 HK$ 88,500
14 lots 7,000 HK$ 103,250
16 lots 8,000 HK$ 118,000
18 lots 9,000 HK$ 132,750
20 lots 10,000 HK$ 147,500
30 lots 15,000 HK$ 221,250
40 lots 20,000 HK$ 295,000
50 lots 25,000 HK$ 368,750
60 lots 30,000 HK$ 442,500
70 lots 35,000 HK$ 516,250
80 lots 40,000 HK$ 590,000
90 lots 45,000 HK$ 663,750
100 lots 50,000 HK$ 737,500
120 lots 60,000 HK$ 885,000
140 lots 70,000 HK$ 1,032,500
160 lots 80,000 HK$ 1,180,000
180 lots 90,000 HK$ 1,327,500
200 lots 100,000 HK$ 1,475,000
400 lots 200,000 HK$ 2,950,000
600 lots 300,000 HK$ 4,425,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
800 lots 400,000 HK$ 5,900,000
1,000 lots 500,000 HK$ 7,375,000
1,200 lots 600,000 HK$ 8,850,000
1,400 lots 700,000 HK$ 10,325,000
1,600 lots 800,000 HK$ 11,800,000
1,800 lots 900,000 HK$ 13,275,000
2,000 lots 1,000,000 HK$ 14,750,000
3,000 lots 1,500,000 HK$ 22,125,000
4,120 lots 2,060,000 HK$ 30,385,000
Valuation & Financials
Market Cap (at Offer Price)HK$ 6,076,681,208
Pre-IPO Valuation (Last Round)To be extracted
P/E Ratio不适用（公司处于亏损状态）
Profit/Loss Status盈利约人民币21.1百万元
Period-End Cash Balance人民币74,800,000元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day Performance
First Day CloseHK$ 38.5
First Day OpenHK$ 47.0
First Day Change161.02%
First Day Volume13550700.0
First Day Turnover610929000.0
Use of Proceeds
Use of Proceeds1、約40.0%或210.2百萬港元將用于為國內及國際的吸入制劑候選產品的持續研發、臨床開發及商業化提供資金； 2、約20.0%或105.1百萬港元將用于為多個管線計劃及技術的臨床前研發提供資金； 3、約30.0%或157.6百萬港元將用于為生產設施、設備采購及生產管理系統的擴張及升級提供資金； 4、約10.0%或52.5百萬港元將用作營運資金及其他一般公司用途。
Underwriting Syndicate
Joint Sponsors (2)
中信证券（香港）有限公司 CE AAK249 招银国际融资有限公司 CE AVM940
Overall Coordinators (3)
中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225
Joint Bookrunners (12)
中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225 东吴证券国际经纪有限公司 CE AYA587 申万宏源证券（香港）有限公司 CE AAC927 浦银国际融资有限公司 CE BFZ375 国证国际证券（香港）有限公司 CE AUW685 工银国际证券有限公司 CE ARO299 中州国际证券有限公司 CE BFI947 交银国际证券有限公司 CE APJ121 农银国际证券有限公司 CE ACX411 国信证券（香港）经纪有限公司 CE AUI491
Joint Lead Managers (12)
中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225 东吴证券国际经纪有限公司 CE AYA587 申万宏源证券（香港）有限公司 CE AAC927 浦银国际融资有限公司 CE BFZ375 国证国际证券（香港）有限公司 CE AUW685 工银国际证券有限公司 CE ARO299 中州国际证券有限公司 CE BFI947 交银国际证券有限公司 CE APJ121 农银国际证券有限公司 CE ACX411 国信证券（香港）经纪有限公司 CE AUI491
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
Chairman梁文青
Company Secretary朱玉玉
No director data available.
Major Shareholders
Major Shareholders & HoldingsSUBSTANTIAL SHAREHOLDERS So far as our Directors are aware, immediately following the completion of the Global Offering and the Conversion of Unlisted Shares into H Shares, the following persons will have interests and/or short positions (as applicable) in the Shares or und
AI AI Analysis
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO attracted staggering demand with an oversubscription ratio of 6697.8x, reflecting extreme market enthusiasm for the biomedical sector. The hit rate of just 3.12% indicates severe allocation scarcity, typical of hot Hong Kong IPOs where retail investors scramble for minimal shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

A notable inefficiency exists between the A-tail and B-head: applying HKD 300,000 yields just 0.0533 expected lots, while HKD 400,000 yields 0.083 lots, offering a minuscule marginal gain of only 0.0297 lots for an extra HKD 100,000. This suggests that the marginal benefit of moving from the top of A-tier to the bottom of B-tier is extremely poor, making lower-tier applications almost as effective. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Demographic data is not available for this IPO, preventing any analysis of mainland China participation, gender, or regional distribution. Without such information, we cannot identify typical patterns like Guangdong dominance or broad cross-border interest. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

AI-generated content. For informational purposes only. Not financial advice. Verify against official sources.
Offering Structure
Subscription Tiers
IPO Timeline
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics